Cargando…
Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study
Attribute-based medicine is essential for patient-centered medicine. To date, the groups of patients with chronic kidney disease (CKD) requiring urate-lowering therapy are clinically unknown. Herein, we evaluated the efficacy of febuxostat using a cross-classification, attribute-based research appro...
Autores principales: | Kataoka, Hiroshi, Mochizuki, Toshio, Ohara, Mamiko, Tsuruta, Yuki, Iwasa, Naomi, Yoshida, Rie, Tsuchiya, Ken, Nitta, Kosaku, Kimura, Kenjiro, Hosoya, Tatsuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904814/ https://www.ncbi.nlm.nih.gov/pubmed/35260678 http://dx.doi.org/10.1038/s41598-022-07737-9 |
Ejemplares similares
-
Sex Differences in Time-Series Changes in Pseudo-R(2) Values Regarding Hyperuricemia in Relation to the Kidney Prognosis
por: Kataoka, Hiroshi, et al.
Publicado: (2020) -
Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014) -
Variation of Urate Transport in the Nephrons in Subtypes of Hyperuricemia
por: Nakamura, Toru, et al.
Publicado: (2013) -
Molecular Elucidation of a Urate Oxidase from Deinococcus radiodurans for Hyperuricemia and Gout Therapy
por: Chiu, Yi-Chih, et al.
Publicado: (2021) -
ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload
por: Matsuo, Hirotaka, et al.
Publicado: (2014)